Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 41 PAGES: 36

More Info
									              Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH57136FSA                                                                                          Publication Date: APR 2013

          One Penn Center, 1617 JFK Blvd                     Phone              +1 215 9880080                  Revenue          0.2 (million USD)
          Philadelphia, PA                                   Fax                +1 215 9881739                  Net Profit       -17.35 (million USD)
          19103                                              Website            www.hemispherx.net              Employees        34
                                                                                HEB [American Stock                              Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company. It develops, manufactures and commercializes drug
       therapies for the treatments of viral and immunebased chronic disorders. The company's products based on two pharmaceutical
       technologies, namely, Ampligen and Alferon N Injection. Hemispherx's lead product, Alferon N Injection is a registered trademark
       for its injectable formulation of Natural Alpha Interferon. The company's product pipeline includes, Ampligen; a treatment of
       Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Alferon LDO (Low Dose Oral), is an oral form of Alferon N
       Injection.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Hemispherx Biopharma, Inc., SWOT Analysis
         William A. Carter, M.D.             Chairman                                 Strengths                              Weaknesses
         Thomas K. Equels                    General Counsel
                                                                                      Strong Patent Portfolio                History of Losses
         Richard C. Piani                    Director
                                                                                      Orphan Drug Designation:               Lack of Revenue from
         Iraj Eqhbal Kiani, Ph.D.            Director
                                                                                      Ampligen                               Marketed Products
         William M. Mitchell, M.D., Director
         Ph.D.
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Changing Demographics                  Competitive Environment
       Share Data
                                                                                      Enhancement of Manufacturing Stringent Government
         Hemispherx Biopharma, Inc.
                                                                                      Plant                        Regulations
        Share Price (USD) as on 22-Apr-                                  0.22
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.12        GlobalData
        Market Cap (million USD)                                           36
        Enterprise Value (million USD)                                     41
        Shares Outstanding (million)                                     167
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 18, 2013         Hemispherx Biopharma Reports 2012 Results
                                                                                      Nov 02, 2012         Hemispherx Biopharma Reports Q3 2012
                                                                                                           Results
                                                                                      Aug 08, 2012         Hemispherx Biopharma Reports Q2 2012
                                                                                                           Results
                                                                                      May 07, 2012         Hemispherx Biopharma Reports Q1 2012
                                                                                                           Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData

       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT                                                                Reference Code: GDPH57136FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Hemispherx Biopharma, Inc. - Key Facts ........................................................................................................................................... 5
       Hemispherx Biopharma, Inc. - Key Employees .................................................................................................................................. 6
       Hemispherx Biopharma, Inc. - Key Employee Biographies ................................................................................................................ 7
       Hemispherx Biopharma, Inc. - Major Products and Services ............................................................................................................. 8
       Hemispherx Biopharma, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 9
          Hemispherx Biopharma, Inc., Pipeline Products by Therapy Area ................................................................................................. 9
          Hemispherx Biopharma, Inc., Pipeline Products by Development Phase ..................................................................................... 10
       Hemispherx Biopharma, Inc. - History .............................................................................................................................................. 12
       Hemispherx Biopharma, Inc. - Company Statement ........................................................................................................................ 13
       Hemispherx Biopharma, Inc. - Locations And Subsidiaries .............................................................................................................. 14
          Head Office ................................................................................................................................................................................... 14
          Other Locations & Subsidiaries ..................................................................................................................................................... 14
       Hemispherx Biopharma, Inc. - Key Manufacturing Facilities ............................................................................................................ 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Hemispherx Biopharma, Inc. - Business Description........................................................................................................................ 16
       Hemispherx Biopharma, Inc. - SWOT Analysis ................................................................................................................................ 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Hemispherx Biopharma, Inc. - Strengths ...................................................................................................................................... 17
             Strength - Strong Patent Portfolio ............................................................................................................................................. 17
             Strength - Orphan Drug Designation: Ampligen ........................................................................................................................ 17
             Strength - Lead Product Alferon N Injection .............................................................................................................................. 17
          Hemispherx Biopharma, Inc. - Weaknesses ................................................................................................................................. 17
             Weakness - History of Losses ................................................................................................................................................... 17
             Weakness - Lack of Revenue from Marketed Products ............................................................................................................ 18
          Hemispherx Biopharma, Inc. - Opportunities ................................................................................................................................ 18
             Opportunity - Changing Demographics ..................................................................................................................................... 18
             Opportunity - Enhancement of Manufacturing Plant .................................................................................................................. 18
             Opportunity - Strategic Partnerships ......................................................................................................................................... 19
          Hemispherx Biopharma, Inc. - Threats ......................................................................................................................................... 19
             Threat - Competitive Environment ............................................................................................................................................. 19
             Threat - Stringent Government Regulations .............................................................................................................................. 19
             Threat - Uncertainties in R&D ................................................................................................................................................... 19
       Hemispherx Biopharma, Inc. - Key Competitors............................................................................................................................... 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26


Hemispherx Biopharma, Inc. (HEB) - Financial and Strategic SWOT                                                                                                Reference Code: GDPH57136FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ............................................... 26
          Hemispherx Biopharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .............................................. 27
       Hemispherx Biopharma, Inc., Recent Deals Summary .................................................................................................................... 28
       Section 5 –
								
To top